TC BioPharm Ltd ( TCBP ) shares are trading lower by 44% to $2.00 Wednesday morning after the company announced the pricing of an offering of 2 million units at $1 per unit.

The clinical-stage biotech company also issued 2 million Series G warrants with an exercise price of £0.78. TC BioPharm ( TCBP ) plans to use the funds raised from the offering to support its upcoming clinical trial for relapse/refractory Acute Myeloid Leukemia, as well as for ongoing operating expenses and working capital.

Read Also: UBS Q2 Earnings Beats: Wealth Management Shines, Cost Savings Accelerate & More

Should I Sell My TCBP Stock?

When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.

Shares of TC BioPharm ( TCBP ) have decreased by 96.36% in the past year. An investor who bought shares of TC BioPharm ( TCBP ) at the beginning of the year would take a loss of $27.65 per share if they sold it today. The stock has fallen 59.44% over the past month, meaning an investor who bought shares on Jul. 1 would see a capital loss of $5.26.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. TC BioPharm ( TCBP ) stock currently has an RSI of 20.56, indicating oversold conditions.

For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.